Quanterix Corporation, based in Billerica, MA, is a leading provider of ultrasensitive biomarker detection technology and precision instruments for the healthcare industry. Their Simoa technology enables researchers to detect biomarkers at lower levels, revolutionizing disease detection, prognosis, and treatment methods. With a wide range of assay kits, custom assay development services, and precision instruments, Quanterix empowers researchers to make breakthrough discoveries in neurology, oncology, immunology, inflammation, infectious diseases, and cardiology.
Quanterix's Simoa technology has been widely recognized for its impact in the fields of oncology, neurology, cardiology, inflammation, and infectious diseases, with hundreds of peer-reviewed publications showcasing its effectiveness. Their ultrasensitive bead and planar array platforms allow for the quantification of key targets at baseline and disease levels, enabling researchers to closely examine critical biomarkers. With a commitment to precision science and a focus on catalyzing scientific advancements, Quanterix is at the forefront of transforming the future of healthcare.
Generated from the website